eligibility_summary
Inclusion: ≥18, measurable epithelial ovarian cancer (incl carcinosarcoma), B7‑H3 tissue/biopsy, ≥1 prior platinum, platinum‑ref/resist, washout ≥3 wks (ICIs 3 mo), ECOG 0–2, adequate marrow/renal/hepatic/coag/cardiac (EF≥45%), O2>92%, neg pregnancy + contraception, consent. Exclude: active infection, steroids >5 mg/d, GI fistula/perf/abscess, other recent CA, major cardiac dz, active autoimmune, active HIV/HBV/HCV, untreated brain mets, allergy to agents, significant seizures, other risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: B7-H3CART—autologous, gene-modified chimeric antigen receptor (CAR) T-cell therapy administered intraperitoneally or intravenously (Phase 1, 3+3 escalation). Mechanism: patient T cells are engineered ex vivo to express a CAR that binds B7-H3 (CD276) on tumor cells, antigen engagement activates CD3ζ and costimulatory signaling, driving T-cell proliferation, cytokine release, and direct cytotoxic killing. Targets: B7-H3–expressing ovarian cancer cells (peritoneal and extra-peritoneal), pathways include B7 family ligand recognition and downstream T-cell effector/tumor lysis mechanisms. Type: autologous cellular immunotherapy.